Interactive Case-Lecture Series:

Advances in Treating Metastatic Castration Resistant Prostate Cancer

UroToday premiers a new, case study-based, mini-lecture series for clinicians treating urologic cancers, specifically metastatic castrate-resistant prostate cancer (mCRPC).

The series currently includes 3 lectures with more to be added.

Treatment of chemotherapy-naive metastatic castration-resistant prostate cancer, by Bryan Mehlhaff, MD

In this presentation, Bryan Mehlhaff, MD, discusses the treatment history of a 49-year-old prostate cancer patient from the time of diagnosis 2001 through 2012. 

The case lecture presentation will take approximately 12 minutes to complete.

The impact of abiraterone acetate therapy on patient-reported pain and functional status in chemotherapy-naive patients with progressive, metastatic castration-resistant prostate cancer, by Charles J. Ryan, MD

In this presentation, Dr. Ryan discusses quality-of-life results, demonstrating a more real-world view of how patients actually feel and function when receiving abiraterone acetate therapy.

The case lecture presentation will take approximately 20 minutes to complete.

Maximum androgen blockade with abiraterone, by Charles J. Ryan, MD

In this presentation, Charles J. Ryan, MD, Associate Professor of Medicine and Urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco discusses Maximum Androgen Blockade with Abiraterone

The case lecture presentation will take approximately 30 minutes to complete.